select a format

Single User License
USD 2000 INR 128080
Site License
USD 4000 INR 256160
Corporate User License
USD 6000 INR 384240

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Hemophilia B-Pipeline Review, H2 2015

Hemophilia B-Pipeline Review, H2 2015


  • Products Id :- GMDHC7232IDB
  • |
  • Pages: 121
  • |
  • October 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Hemophilia B-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Hemophilia B-Pipeline Review, H2 2015', provides an overview of the Hemophilia B's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hemophilia B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia B and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Hemophilia B

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Hemophilia B and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Hemophilia B products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Hemophilia B pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Hemophilia B

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Hemophilia B pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Hemophilia B Overview 10

Therapeutics Development 11

Pipeline Products for Hemophilia B-Overview 11

Pipeline Products for Hemophilia B-Comparative Analysis 12

Hemophilia B-Therapeutics under Development by Companies 13

Hemophilia B-Therapeutics under Investigation by Universities/Institutes 15

Hemophilia B-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Hemophilia B-Products under Development by Companies 19

Hemophilia B-Products under Investigation by Universities/Institutes 21

Hemophilia B-Companies Involved in Therapeutics Development 22

Alnylam Pharmaceuticals, Inc. 22

Amarna Therapeutics B.V. 23

AstraZeneca Plc 24

Baxalta Incorporated 25

Bayer AG 26

Biogen, Inc. 27

Catalyst Biosciences, Inc. 28

CSL Limited 29

Dimension Therapeutics, Inc. 30

Emergent BioSolutions Inc. 31

Novo Nordisk A/S 32

OPKO Health, Inc. 33

Pfizer Inc. 34

Pharming Group N.V. 35

RegenxBio Inc. 36

rEVO Biologics, Inc. 37

Sangamo BioSciences, Inc. 38

Spark Therapeutics, Inc. 39

uniQure N.V. 40

Hemophilia B-Therapeutics Assessment 41

Assessment by Monotherapy Products 41

Assessment by Target 42

Assessment by Mechanism of Action 44

Assessment by Route of Administration 46

Assessment by Molecule Type 48

Drug Profiles 50

albutrepenonacog alfa-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

ALN-AT3-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

AMT-060-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

AZ-10047130-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

BAX-335-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

BAY-1093884-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

CB-2679d-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

CB-813d-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Cell Therapy for Hemophilia B-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

coagulation factor IX (recombinant)-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

coagulation factor IX (recombinant)-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

coagulation factor IX-Fc (recombinant), Fc fusion protein-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

coagulation factor VIIa (recombinant)-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

concizumab-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

CSL-689-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

DTX-101-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Gene Therapy for Hemophilia B-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

Gene Therapy to Activate Factor IX for Hemophilia B-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

Gene Therapy to Activate Factor IX for Hemophilia B-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

LR-769-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

MOD-5014-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

MOD-9017-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

nonacog beta pegol-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

PF-06741086-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

SB-FIX-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

SPK-FIX-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

SVF-VIIa-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Hemophilia B-Recent Pipeline Updates 88

Hemophilia B-Dormant Projects 110

Hemophilia B-Discontinued Products 111

Hemophilia B-Product Development Milestones 112

Featured News & Press Releases 112

Sep 17, 2015: Dimension Therapeutics Announces FDA Fast Track Designation for Lead Candidate DTX101 in Patients with Hemophilia B 112

Sep 10, 2015: Dimension Therapeutics Announces FDA Acceptance of Investigational New Drug Application and Orphan Drug Designation for Lead Candidate DTX101 in Patients with Hemophilia B 112

Aug 17, 2015: Results from B-YOND Extension Study Reinforce Long-Term Clinical Profile of ALPROLIX for the Treatment of Hemophilia B 113

Jul 28, 2015: Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 114

Jun 26, 2015: Biogen and Sobi Announce European Medicines Agency Validates ALPROLIX (rFIXFc) Marketing Authorization Application 115

Jun 24, 2015: CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015 116

Jun 24, 2015: Baxalta Reports Continued Progress on Phase 1/2 Clinical Trial of BAX335, Investigational Gene Therapy Treatment for Hemophilia B 117

Jun 16, 2015: Catalyst Biosciences Announces CB 2679d Data Presentations at the 2015 International Society on Thrombosis and Haemostatsis Meeting 118

Jun 16, 2015: Catalyst Biosciences Announces PF-05280602 Data Presentations at the 2015 International Society on Thrombosis and Haemostatsis Meeting 118

Jun 04, 2015: Sobi's partner Biogen submits marketing authorisation application for Alprolix (rFIXFc) in Europe 119

Appendix 120

Methodology 120

Coverage 120

Secondary Research 120

Primary Research 120

Expert Panel Validation 120

Contact Us 120

Disclaimer 121

List of Tables

Number of Products under Development for Hemophilia B, H2 2015 11

Number of Products under Development for Hemophilia B-Comparative Analysis, H2 2015 12

Number of Products under Development by Companies, H2 2015 13

Number of Products under Investigation by Universities/Institutes, H2 2015 15

Comparative Analysis by Late Stage Development, H2 2015 16

Comparative Analysis by Clinical Stage Development, H2 2015 17

Comparative Analysis by Early Stage Development, H2 2015 18

Products under Development by Companies, H2 2015 19

Products under Development by Companies, H2 2015 (Contd...1) 20

Products under Investigation by Universities/Institutes, H2 2015 21

Hemophilia B-Pipeline by Alnylam Pharmaceuticals, Inc., H2 2015 22

Hemophilia B-Pipeline by Amarna Therapeutics B.V., H2 2015 23

Hemophilia B-Pipeline by AstraZeneca Plc, H2 2015 24

Hemophilia B-Pipeline by Baxalta Incorporated, H2 2015 25

Hemophilia B-Pipeline by Bayer AG, H2 2015 26

Hemophilia B-Pipeline by Biogen, Inc., H2 2015 27

Hemophilia B-Pipeline by Catalyst Biosciences, Inc., H2 2015 28

Hemophilia B-Pipeline by CSL Limited, H2 2015 29

Hemophilia B-Pipeline by Dimension Therapeutics, Inc., H2 2015 30

Hemophilia B-Pipeline by Emergent BioSolutions Inc., H2 2015 31

Hemophilia B-Pipeline by Novo Nordisk A/S, H2 2015 32

Hemophilia B-Pipeline by OPKO Health, Inc., H2 2015 33

Hemophilia B-Pipeline by Pfizer Inc., H2 2015 34

Hemophilia B-Pipeline by Pharming Group N.V., H2 2015 35

Hemophilia B-Pipeline by RegenxBio Inc., H2 2015 36

Hemophilia B-Pipeline by rEVO Biologics, Inc., H2 2015 37

Hemophilia B-Pipeline by Sangamo BioSciences, Inc., H2 2015 38

Hemophilia B-Pipeline by Spark Therapeutics, Inc., H2 2015 39

Hemophilia B-Pipeline by uniQure N.V., H2 2015 40

Assessment by Monotherapy Products, H2 2015 41

Number of Products by Stage and Target, H2 2015 43

Number of Products by Stage and Mechanism of Action, H2 2015 45

Number of Products by Stage and Route of Administration, H2 2015 47

Number of Products by Stage and Molecule Type, H2 2015 49

Hemophilia B Therapeutics-Recent Pipeline Updates, H2 2015 88

Hemophilia B-Dormant Projects, H2 2015 110

Hemophilia B-Discontinued Products, H2 2015 111

List of Figures

Number of Products under Development for Hemophilia B, H2 2015 11

Number of Products under Development for Hemophilia B-Comparative Analysis, H2 2015 12

Number of Products under Development by Companies, H2 2015 13

Number of Products under Investigation by Universities/Institutes, H2 2015 15

Comparative Analysis by Late Stage Development, H2 2015 16

Comparative Analysis by Clinical Stage Development, H2 2015 17

Comparative Analysis by Early Stage Products, H2 2015 18

Assessment by Monotherapy Products, H2 2015 41

Number of Products by Targets, H2 2015 42

Number of Products by Stage and Top 10 Targets, H2 2015 42

Number of Products by Mechanism of Actions, H2 2015 44

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 44

Number of Products by Routes of Administration, H2 2015 46

Number of Products by Stage and Routes of Administration, H2 2015 46

Number of Products by Molecule Types, H2 2015 48

Number of Products by Stage and Molecule Types, H2 2015 48

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Alnylam Pharmaceuticals, Inc.

Amarna Therapeutics B.V.

AstraZeneca Plc

Baxalta Incorporated

Bayer AG

Biogen, Inc.

Catalyst Biosciences, Inc.

CSL Limited

Dimension Therapeutics, Inc.

Emergent BioSolutions Inc.

Novo Nordisk A/S

OPKO Health, Inc.

Pfizer Inc.

Pharming Group N.V.

RegenxBio Inc.

rEVO Biologics, Inc.

Sangamo BioSciences, Inc.

Spark Therapeutics, Inc.

uniQure N.V.

Hemophilia B Therapeutic Products under Development, Key Players in Hemophilia B Therapeutics, Hemophilia B Pipeline Overview, Hemophilia B Pipeline, Hemophilia B Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com